Harel Dahari
  • Assistant Professor
  • Hepatology

Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kineticsDahari,H.; Shteingart,S.; Gafanovich,I.; Cotler,S. J.; D'Amato,M.; Pohl,R. T.; Weiss,G.; Ashkenazi,Y. J.; Tichler,T.; Goldin,E.; Lurie,Y.Liver international : official journal of the International Association for the Study of the Liver 2014 ; ( ):

Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modelingGuedj,J.; Rotman,Y.; Cotler,S. J.; Koh,C.; Schmid,P.; Albrecht,J.; Haynes-Williams,V.; Liang,J. T.; Hoofnagle,J. H.; Heller,T.; Dahari,H.Hepatology (Baltimore, Md.) 2014 ; ( ):

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeGuedj,J.; Dahari,H.; Rong,L.; Sansone,N. D.; Nettles,R. E.; Cotler,S. J.; Layden,T. J.; Uprichard,S. L.; Perelson,A. S.Proceedings of the National Academy of Sciences of the United States of America 2013 ;110(10):3991-3996

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis CRotman,Y.; Noureddin,M.; Feld,J. J.; Guedj,J.; Witthaus,M.; Han,H.; Park,Y. J.; Park,S. H.; Heller,T.; Ghany,M. G.; Doo,E.; Koh,C.; Abdalla,A.; Gara,N.; Sarkar,S.; Thomas,E.; Ahlenstiel,G.; Edlich,B.; Titerence,R.; Hogdal,L.; Rehermann,B.; Dahari,H.; Perelson,A. S.; Hoofnagle,J. H.; Liang,T. J.Gut 2013 ; ( ):

Individualized treatment for patients with low HCV load (genotype 1): A viral kinetic approachDahari,H.; Cotler,S. J.Hepatology (Baltimore, Md.) 2013 ; ( ):

Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modelingDahari,H.; Cotler,S. J.; Layden,T. J.; Perelson,A. S.Journal of Hepatology 2013 ;58(4):840-842

Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale modelRong,L.; Guedj,J.; Dahari,H.; Coffield,D. J.,Jr; Levi,M.; Smith,P.; Perelson,A. S.PLoS computational biology 2013 ;9(3):e1002959

Silymarin for HCV infectionPolyak,S. J.; Oberlies,N. H.; Pecheur,E. I.; Dahari,H.; Ferenci,P.; Pawlotsky,J. M.ANTIVIRAL THERAPY 2013 ;18(2):141-147

Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infectionZhang,J.; Lipton,H. L.; Perelson,A. S.; Dahari,H.Journal of virology 2013 ;87(7):4052-4059

The rate of hepatitis C virus infection initiation in vitro is directly related to particle densitySabahi,A.; Marsh,K. A.; Dahari,H.; Corcoran,P.; Lamora,J. M.; Yu,X.; Garry,R. F.; Uprichard,S. L.Virology 2010 ;407(1):110-119

Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferonDahari,H.; Sainz,B.,Jr; Perelson,A. S.; Uprichard,S. L.Journal of virology 2009 ;83(13):6383-6390